TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01236742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ortho-k lenses
Description: nightly wear of orthokeratology lenses to correct vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ortho-k lenses
Description: nightly wear of orthokeratology lenses to correct vision

Intervention type: DEVICE
Group type: OTHER
Intervention: single-vision glasses
Description: daily wear of spectacle glasses to correct vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-vision glasses
Description: daily wear of spectacle glasses to correct vision
Study: NCT04099277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3435151
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT05198401

Intervention type: OTHER
Intervention: covid-19
Description: viral infection
Study: NCT04592341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
Study: NCT04032821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib（300mg)
Description: 1. First empty stomach, after the meal.2. After eating first, after fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib（300mg)
Description: 1. First empty stomach, after the meal.2. After eating first, after fasting.
Study: NCT01369212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: 300 mg daily for 192 weeks (4 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa 2a and tenofovir
Description: A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
Study: NCT04557163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142 will be given as 1 mg per capsule administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will given as 50 mg per capsule administered orally with water.
Study: NCT04107558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
Study: NCT01013168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis using the OncoSorb column
Description: device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
Study: NCT02762019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
Study: NCT03794752

Intervention type: DEVICE
Group type: OTHER
Intervention: Head-Mounted Visual Enhancement Device
Description: Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black \& white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
Study: NCT02452801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Single dose, given orally
Study: NCT00869388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBBX-01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBBX-01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBBX-01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBBX-01
Study: NCT00312299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Square edge PMMA IOL
Description: Arm 1 A - Square edge PMMA IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Round edge PMMA IOL
Description: Round edge PMMA IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof IOL
Description: Acrysof IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: square Edge PMMA IOL
Description: Square edge PMMA intra ocular lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Square Edge PMMA IOL
Description: Square Edge PMMA IOL lens
Study: NCT01079429

Intervention type: GENETIC
Intervention: Genetic study of DNA copies
Description: Gene expression profiling, DNA copy number variation
Study: NCT01824264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Experimental treatment doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Active comparator treatment dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator dose
Study: NCT01795586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m\^2; Level 2: 1.1 mg/m\^2; Level 3: 1.4 mg/m\^2
Study: NCT00709761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib/nab-Paclitaxel
Description: This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
Study: NCT05112471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airflow, Perioflow and Erythritol powder and ultrasonic debridement
Description: Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic debridement and curettes
Description: traditional Scaling and Root Planing with curettes and ultrasonic scaler
Study: NCT01795586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
Study: NCT00874679

Intervention type: DRUG
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
Study: NCT04446026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teneligliptin
Description: teneligliptin 20mg PO qd for 24weeks
Study: NCT01113567

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose-free milk
Description: 3.5 g of lactose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole milk
Description: Whole milk with 24 g lactose
Study: NCT02400333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
Description: 90 mg single dose
Study: NCT04446026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
Study: NCT01818388

Intervention type: DEVICE
Intervention: ZOLL Intravascular Temperature Management System (IVTM)
Description: Induced therapeutic hypothermia post cardiac arrest.
Study: NCT03638882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duolingo
Description: Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BrainHQ
Description: Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive Control
Description: No Intervention.
Study: NCT01913808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Single intravenous dose ferric carboxymaltose
Study: NCT02400333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
Description: 90 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
Description: 90 mg single dose
Study: NCT01301352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Route of feeding (nasogastric vs. nasojejunal)
Description: Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
Study: NCT03646318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin
Description: The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose 5% solution
Study: NCT00401531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
Description: 0.5 mL, IM
Study: NCT00717197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
Study: NCT01275885

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (D3)
Description: 10µg (400 IU) orally daily for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (D3)
Description: 30µg (1200 IU) orally daily for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (D3)
Description: 40µg (1600 IU) orally daily for 10 weeks
Study: NCT00117481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2001a
Description: DR-2001a administered vaginally each month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2001b
Description: DR-2001b administered vaginally each month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered vaginally each month
Study: NCT00571545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No exercise
Description: Controls were wait-listed for the exercise program during the 10 week study period.
Study: NCT03663998

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).
Study: NCT03578237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis (active)
Description: Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
Study: NCT03663998

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54ENV DNA
Description: CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s).
Study: NCT01281111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (BG00012)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (BG00012)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (BG00012)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BG00012 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA matching placebo
Study: NCT01160809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mosquito repellent
Description: Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
Study: NCT00527228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deflazacort
Description: In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03663998

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GENEVAX® IL-12 DNA
Description: GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GENEVAX® IL-12 DNA
Description: GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration.
Study: NCT02975336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M2951 orally for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants received 75 mg of M2951 orally QD for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
Study: NCT01913808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous glycine sulphate
Description: Daily oral dose of 100 mg iron (ferrous glycine sulphate)
Study: NCT01157052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (supplement) Calcium and Magnesium
Description: FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (supplement) Calcium and Magnesium
Description: FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)
Study: NCT03102216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8